BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors
BRCA promotor hypermethylation seems to be a rare event in metastatic BC but is preserved in subsequent xenograft models and might represent an attractive therapeutic marker for PARP inhibitors.
Authors
- Kavitha Däster (ORCID: https://orcid.org/0000-0002-3292-5994)
- Marta Palafox (ORCID: https://orcid.org/0000-0002-1762-3250)
- Maren Diepenbruck
- Adelin Rouchon
- Katrin Volkmann
- Jorge Gómez Miragaya
- Simone E. Muenst (ORCID: https://orcid.org/0000-0001-7973-1401)
- Savas D. Soysal (ORCID: https://orcid.org/0000-0002-0761-449X)
- William P. Weber (ORCID: https://orcid.org/0000-0003-1667-7844)
- Mohamed Bentires‐Alj (ORCID: https://orcid.org/0000-0001-6344-1127)
- Christian Kurzeder (ORCID: https://orcid.org/0000-0002-9362-3033)
- Jürgen Hench
- Bogdan Tiberius Preca
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
- Breast Center (CH)
- Immunologie-Zentrum Zürich (CH)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1007/s10549-024-07502-8
- Citations
- 5
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.75
Funders
- Universität Basel
- Illumina